153 related articles for article (PubMed ID: 33430710)
21. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
22. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
[TBL] [Abstract][Full Text] [Related]
23. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms.
Arcaini L; Zibellini S; Boveri E; Riboni R; Rattotti S; Varettoni M; Guerrera ML; Lucioni M; Tenore A; Merli M; Rizzi S; Morello L; Cavalloni C; Da Vià MC; Paulli M; Cazzola M
Blood; 2012 Jan; 119(1):188-91. PubMed ID: 22072557
[TBL] [Abstract][Full Text] [Related]
24. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
[TBL] [Abstract][Full Text] [Related]
25. Molecular Correlates and Nuclear Features of Encapsulated Follicular-Patterned Thyroid Neoplasms.
Jung CK; Bychkov A; Song DE; Kim JH; Zhu Y; Liu Z; Keelawat S; Lai CR; Hirokawa M; Kameyama K; Kakudo K
Endocrinol Metab (Seoul); 2021 Feb; 36(1):123-133. PubMed ID: 33677934
[TBL] [Abstract][Full Text] [Related]
26. BRAFV600E Immunohistochemistry in Papillary Thyroid Carcinomas: Relationship Between Clinical and Morphological Parameters.
Kombak FE; Özkan N; Uğurlu MÜ; Kaya H
Turk Patoloji Derg; 2019; 35(2):83-91. PubMed ID: 30632125
[TBL] [Abstract][Full Text] [Related]
27. BRAF and RAS mutations in follicular variants of papillary thyroid carcinoma.
Park JY; Kim WY; Hwang TS; Lee SS; Kim H; Han HS; Lim SD; Kim WS; Yoo YB; Park KS
Endocr Pathol; 2013 Jun; 24(2):69-76. PubMed ID: 23625203
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia.
Schnittger S; Bacher U; Haferlach T; Wendland N; Ulke M; Dicker F; Grossmann V; Haferlach C; Kern W
Blood; 2012 Mar; 119(13):3151-4. PubMed ID: 22331186
[TBL] [Abstract][Full Text] [Related]
29. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations.
Jung CK; Little MP; Lubin JH; Brenner AV; Wells SA; Sigurdson AJ; Nikiforov YE
J Clin Endocrinol Metab; 2014 Feb; 99(2):E276-85. PubMed ID: 24248188
[TBL] [Abstract][Full Text] [Related]
30. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
Cheng L; Jin Y; Liu M; Ruan M; Chen L
Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
[TBL] [Abstract][Full Text] [Related]
31. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro.
Ullmann TM; Liang H; Moore MD; Al-Jamed I; Gray KD; Limberg J; Stefanova D; Buicko JL; Finnerty B; Beninato T; Zarnegar R; Min IM; Fahey TJ
Surgery; 2020 Jan; 167(1):56-63. PubMed ID: 31585718
[TBL] [Abstract][Full Text] [Related]
32. BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.
Cornea MI; Levrat E; Pugin P; Betticher DC
J Med Case Rep; 2015 Apr; 9():30. PubMed ID: 26187587
[TBL] [Abstract][Full Text] [Related]
33. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.
Pettirossi V; Santi A; Imperi E; Russo G; Pucciarini A; Bigerna B; Schiavoni G; Fortini E; Spanhol-Rosseto A; Sportoletti P; Mannucci R; Martelli MP; Klein-Hitpass L; Falini B; Tiacci E
Blood; 2015 Feb; 125(8):1207-16. PubMed ID: 25480661
[TBL] [Abstract][Full Text] [Related]
34. BRAF V600E mutation in hairy cell leukemia: from bench to bedside.
Falini B; Martelli MP; Tiacci E
Blood; 2016 Oct; 128(15):1918-1927. PubMed ID: 27554081
[TBL] [Abstract][Full Text] [Related]
35. BRAF(V600E) mutation together with loss of Trp53 or pTEN drives the origination of hairy cell leukemia from B-lymphocytes.
Yap J; Yuan J; Ng WH; Chen GB; Sim YRM; Goh KC; Teo J; Lim TYH; Goay SM; Teo JHJ; Lao Z; Lam P; Sabapathy K; Hu J
Mol Cancer; 2023 Aug; 22(1):125. PubMed ID: 37543582
[TBL] [Abstract][Full Text] [Related]
36. Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.
Blachly JS; Lozanski G; Lucas DM; Grever MR; Kendra K; Andritsos LA
J Natl Compr Canc Netw; 2015 Jan; 13(1):9-13; quiz 13. PubMed ID: 25583765
[TBL] [Abstract][Full Text] [Related]
37. Exploration of BRAFV600E as a diagnostic adjuvant in the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).
Johnson DN; Sadow PM
Hum Pathol; 2018 Dec; 82():32-38. PubMed ID: 30146440
[TBL] [Abstract][Full Text] [Related]
38. MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.
Knippler CM; Saji M; Rajan N; Porter K; La Perle KMD; Ringel MD
Endocr Relat Cancer; 2019 Aug; 26(8):699-712. PubMed ID: 31146260
[TBL] [Abstract][Full Text] [Related]
39. Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation.
Afkhami M; Karunamurthy A; Chiosea S; Nikiforova MN; Seethala R; Nikiforov YE; Coyne C
Thyroid; 2016 Feb; 26(2):242-7. PubMed ID: 26422023
[TBL] [Abstract][Full Text] [Related]
40. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
